Company’s 36-month beta value is 0.74.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 6 as “overweight,” 2 as “hold,” and 1 as “sell.”
The public float for IMCR is 48.66M, and currently, short sellers hold a 14.50% ratio of that floaft. The average trading volume of IMCR on December 27, 2024 was 275.02K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IMCR) stock’s latest price update
The stock of Immunocore Holdings plc ADR (NASDAQ: IMCR) has increased by 5.44 when compared to last closing price of 28.66. Despite this, the company has experienced a 6.94% gain in its stock price over the last five trading sessions. zacks.com reported 2024-12-26 that Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.
IMCR’s Market Performance
Immunocore Holdings plc ADR (IMCR) has seen a 6.94% rise in stock performance for the week, with a -7.84% decline in the past month and a -1.79% plunge in the past quarter. The volatility ratio for the week is 5.02%, and the volatility levels for the past 30 days are at 4.85% for IMCR. The simple moving average for the past 20 days is -0.75% for IMCR’s stock, with a -26.49% simple moving average for the past 200 days.
Analysts’ Opinion of IMCR
Many brokerage firms have already submitted their reports for IMCR stocks, with Morgan Stanley repeating the rating for IMCR by listing it as a “Equal-Weight.” The predicted price for IMCR in the upcoming period, according to Morgan Stanley is $35 based on the research report published on December 13, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see IMCR reach a price target of $38, previously predicting the price at $72. The rating they have provided for IMCR stocks is “Neutral” according to the report published on November 11th, 2024.
UBS gave a rating of “Sell” to IMCR, setting the target price at $24 in the report published on October 24th of the current year.
IMCR Trading at -5.20% from the 50-Day Moving Average
After a stumble in the market that brought IMCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.74% of loss for the given period.
Volatility was left at 4.85%, however, over the last 30 days, the volatility rate increased by 5.02%, as shares sank -6.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.50% lower at present.
During the last 5 trading sessions, IMCR rose by +6.94%, which changed the moving average for the period of 200-days by -50.65% in comparison to the 20-day moving average, which settled at $30.45. In addition, Immunocore Holdings plc ADR saw -55.77% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMCR starting from St Leger Tina Amber, who sale 4,375 shares at the price of $64.06 back on Apr 01 ’24. After this action, St Leger Tina Amber now owns 0 shares of Immunocore Holdings plc ADR, valued at $280,262 using the latest closing price.
Berman David M, the HEAD OF R&D of Immunocore Holdings plc ADR, sale 36,509 shares at $68.59 during a trade that took place back on Feb 28 ’24, which means that Berman David M is holding 0 shares at $2,504,158 based on the most recent closing price.
Stock Fundamentals for IMCR
Current profitability levels for the company are sitting at:
- -0.23 for the present operating margin
- 0.99 for the gross margin
The net margin for Immunocore Holdings plc ADR stands at -0.16. The total capital return value is set at -0.09. Equity return is now at value -12.85, with -5.71 for asset returns.
Based on Immunocore Holdings plc ADR (IMCR), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 1.16. The interest coverage ratio of the stock is -6.91.
Currently, EBITDA for the company is -51.65 million with net debt to EBITDA at 1.29. When we switch over and look at the enterprise to sales, we see a ratio of 4.39. The receivables turnover for the company is 5.21for trailing twelve months and the total asset turnover is 0.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.78.
Conclusion
In a nutshell, Immunocore Holdings plc ADR (IMCR) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
